ArticleBreast cancer research : BCR2004
Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.
Article in Breast cancer research : BCR, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 342 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
342 citing papers in PubMed, 2 syntheses or guidelines pooled it, 858 citations in OpenAlex.
- Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma.British journal of cancer · 2023Pooled it
- Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery-A systematic review and meta-analysis.Breast (Edinburgh, Scotland) · 2022Pooled it
- PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.Nature cancer · 2023Trial
- Accurate assessment of surgical HER2-low status based on core needle biopsy data of breast cancer.Diagnostic and prognostic research · 2026Article
- Long-term outcomes of invasive lobular carcinoma compared with invasive ductal carcinoma in HR-positive/HER2-negative breast cancer: a focus on luminal subtypes.Breast cancer (Tokyo, Japan) · 2026Article
- Metastasis of Invasive Ductal Carcinoma of the Breast to the Uterine Cervix 30 Years Post-Mastectomy: A Case Report.The journal of obstetrics and gynaecology research · 2026Article
- Clinical Impact and Outcomes of Neoadjuvant Systemic Therapy for Invasive Lobular Carcinoma.Annals of surgical oncology · 2026Article
- Long-term Outcomes of Slowly Proliferating Luminal A-like Invasive Lobular Carcinoma Versus Invasive Carcinoma of No Special Type.Journal of breast cancer · 2026Article
- Breast cancer ovarian metastases show increased activity of GPCR pathways.bioRxiv : the preprint server for biology · 2026Article
- Geographic Differences in Patient Experience After a Diagnosis of Lobular Breast Cancer.Annals of surgical oncology · 2026Article
- Comparative analysis of the diagnostic value of dynamic contrast-enhanced magnetic resonance imaging kinetic heterogeneity and apparent diffusion coefficient for grading invasive breast cancer.Diagnostic and interventional radiology (Ankara, Turkey) · 2026Article
- Integrating multi-omics and clinical management in breast cancer: a comprehensive review.Discover oncology · 2026Review
- Restoration of E-cadherin Expression Alters Metastatic Organotropism in Invasive Lobular Breast Carcinoma Models.bioRxiv : the preprint server for biology · 2026Article
- Article
- Invasive ductal and lobular carcinoma and receptor status in the genetic context of breast cancer.Scientific reports · 2026Article
- A prospective single-arm pilot study evaluating [F-18]fluoroestradiol dedicated breast PET in invasive lobular carcinoma after neoadjuvant endocrine therapy.Breast cancer research : BCR · 2026Article
- Estrogen receptor-positive cell line xenograft models recapitulate metastatic dissemination and endocrine response of invasive lobular breast carcinoma.bioRxiv : the preprint server for biology · 2026Article
- Invasive lobular carcinoma of the breast with multifocal gastrointestinal, ovarian, and peritoneal metastases: a case report.Journal of medical case reports · 2026Article
- Metastatic lobular breast cancer masquerading as achalasia.VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy · 2026Article
- Breast Cancer Metastasis to the Gastrointestinal Tract After Nine Years of Remission: A Case Report.Cureus · 2026Article
282 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
Abstract
introductionInvasive lobular carcinoma (ILC) comprises approximately 10% of breast cancers and appears to have a distinct biology. Because it is less common than infiltrating ductal carcinoma (IDC), few data have been reported that address the biologic features of ILC in the context of their clinical outcome. In the present study we undertook an extensive comparison of ILC and IDC using a large database to provide a more complete and reliable assessment of their biologic phenotypes and clinical behaviors.
methodsThe clinical and biological features of 4140 patients with ILC were compared with those of 45,169 patients with IDC (not otherwise specified). The median follow-up period was 87 months.
resultsIn comparison with IDC, ILC was significantly more likely to occur in older patients, to be larger in size, to be estrogen and progesterone receptor positive, to have lower S-phase fraction, to be diploid, and to be HER-2, p53, and epidermal growth factor receptor negative. It was more common for ILC than for IDC to metastasize to the gastrointestinal tract and ovary. The incidence of contralateral breast cancer was higher for ILC patients than for IDC patients (20.9% versus 11.2%; P < 0.0001). Breast preservation was modestly less frequent in ILC patients than in IDC patients. The 5-year disease-free survival was 85.7% for ILC and 83.5% for IDC (P = 0.13). The 5-year overall survival was 85.6% for ILC and 84.1% for IDC (P = 0.64).
conclusionDespite the fact that the biologic phenotype of ILC is quite favorable, these patients do not have better clinical outcomes than do patients with IDC. At present, management decisions should be based on individual patient and tumor biologic characteristics, and not on lobular histology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.